|
|
| | (R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Basic information |
| Product Name: | (R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate | | Synonyms: | 1-Piperidinecarboxylic acid, 3-[4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]-, 1,1-diMethylethyl ester, (3R)-;(R)-tert-Butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate;(R)-tert-Butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate (N-1);3-[4-Amino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-piperidine-1-carboxylic acid tert-butyl ester;Ibrutinib Intermediates;(R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-ca;(R)-1-(1-Boc-3-piperidinyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;(R)-3-[4-Amino-3-(4-phenoxy-phenyl)-
pyrazolo[3,4-d]pyrimidin-1-yl]-
piperidine-1-carboxylic acid tert-butyl ester | | CAS: | 1022150-11-3 | | MF: | C27H30N6O3 | | MW: | 486.57 | | EINECS: | | | Product Categories: | | | Mol File: | 1022150-11-3.mol | ![(R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Structure](CAS/20150408/GIF/1022150-11-3.gif) |
| | (R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Chemical Properties |
| Boiling point | 673.9±55.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | DMSO (Slightly), Ethyl Acetate (Slightly) | | pka | 4.09±0.30(Predicted) | | form | Solid | | color | White to Off-White | | InChIKey | NTSAEGNFPKKRLX-LJQANCHMSA-N | | SMILES | N1(C(OC(C)(C)C)=O)CCC[C@@H](N2C3C(C(C4=CC=C(OC5=CC=CC=C5)C=C4)=N2)=C(N)N=CN=3)C1 |
| | (R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Usage And Synthesis |
| Uses | N-Boc-Ibrutinib is an impurity of Ibrutinib (I124970), which is a highly selective Bruton’s tyrosine kinase (Btk) irreversible inhibitor. | | Synthesis | 3-(4-phenoxyphenyl) lH-pyrazolo [3,4-d] pyrimidin-4-amine (1.14g, 3.76mmol)was dissolved DMF (30mL) in, and then the reaction solution was added (S)-tert-butyl 3-((methylsulfonyl) oxy) piperidine-1-carboxylate (4.2g, 15.04mmol), cesium carbonate(0.64mL, 8.21 mmol), 4- dimethylaminopyridine pyridine (3.67g, 11.28mmol). Was stirred at 90 ℃, the reaction was completed, distilled under reduced pressure of DMF, and extracted with dichloromethane (150mL × 3), brine (60mL), dried over anhydrous sodium sulfate; the solvent was distilled off under reduced pressure, the crude product was silica gel column Analysis of separation and purification (methylene chloride /methanol (V / V) = 40/1), to give the product (R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate (1.28 g, 70 percent).
| | References | [1] Patent: WO2012/158795, 2012, A1. Location in patent: Page/Page column 76 [2] Patent: WO2013/191965, 2013, A1. Location in patent: Page/Page column 156 [3] Patent: WO2014/22569, 2014, A1. Location in patent: Page/Page column 50 [4] Patent: US8673925, 2014, B1. Location in patent: Page/Page column 201 [5] Patent: CN106146511, 2016, A. Location in patent: Paragraph 0150; 0151; 0152 |
| | (R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate Preparation Products And Raw materials |
|